crc cell line sw480  (Procell Inc)

Journal: Redox Biology

Article Title: Targeting HIF-1α promotes ferroptosis and boosts antitumor immunity in MSS colorectal cancer

doi: 10.1016/j.redox.2026.104151

Figure Lengend Snippet: A hypoxia-characteristic cluster identified by Microwell-seq exhibited pronounced ferroptosis resistance in MSS CRC cells. (A and B) t-distributed stochastic neighbor embedding (t-SNE) plot of Microwell-seq analysis based on gene expressions of SW480 and WiDr. (C and D) Comparative gene set enrichment analysis (GSEA) of signaling pathways in different clusters. The red color represents up-regulation and blue represents down-regulation, calculated with the formula: ± Log2|NES/p.adjust|. Grey color represents no enrichment in the indicated pathway. NES: normalized enrichment score. (E and F) GSEA analysis showed the indicated pathway activity between the hypoxia cluster and other clusters. (G and H) Correlation analysis of hypoxia scores, glycolysis scores, and ferroptosis suppressor scores in WiDr and SW480 cells was performed using Pearson's method. (I and J) The ferroptosis suppressor score of SW480 and WiDr with DMSO or RSL3 treatment was analyzed by AddModuleScore tool. P values were calculated by Wilcox.test. (K and L) The ferroptosis suppressor score of hypoxia cluster in SW480 and WiDr treated with DMSO or RSL3 was shown. P values were calculated by Wilcox.test.

Article Snippet: The human MSS CRC cell lines SW480, HT-29, and WiDr, human HEK293T, and mouse MSS CRC cell line CT26 were obtained from American Type Culture Collection (ATCC).

Techniques: Protein-Protein interactions, Activity Assay

Journal: Redox Biology

Article Title: Targeting HIF-1α promotes ferroptosis and boosts antitumor immunity in MSS colorectal cancer

doi: 10.1016/j.redox.2026.104151

Figure Lengend Snippet: HIF-1α nuclear distribution increased in RSL3-resistant CT26 cells and significantly promoted tumourigenicity and metastasis. (A) The diagram demonstrated the procedure for sphere formation. (B and C) The representative images of sphere formation in MSS CRC cells and quantification analysis of sphere number derived from SW480, HT-29, and WiDr. (D) HIF-1α expression in WiDr was detected by western blotting. (E) qPCR analyzed the indicated gene expression involved in glycolysis in WiDr spheres. (F) Cell viability of parental CT26 and RSL3-resistant CT26 (Re-CT26). (G) Cytoplasm and nuclear HIF-1α expression in CT26. α-tubulin was used as an internal reference for the cytoplasm, and Histone 3 was used as a nuclear reference. (H) qPCR analyzed the indicated gene expression involved in glycolysis in CT26. (I) Image of subcutaneous tumors derived from parental CT26 and Re-CT26. (J) Tumor volume determined by formula: 0.52 × Long × width 2 . (K)Tumor weight of subcutaneous tumors. (L) Bioluminescent images in liver metastatic models. (M) Images of liver metastasis derived from parental CT26 and Re-CT26. (N) Number of liver nodules in liver metastasis models. (O) Representative hematoxylin and eosin (H&E) and immunohistochemical staining images from liver metastasis models. Scale bar: 25 μm. (P) Quantification of immunohistochemical staining results shown in (O). Data are shown as means ± SD. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ns: not significant. Two-way ANOVA in (J), others unpaired two-tailed Student's t -test.

Article Snippet: The human MSS CRC cell lines SW480, HT-29, and WiDr, human HEK293T, and mouse MSS CRC cell line CT26 were obtained from American Type Culture Collection (ATCC).

Techniques: Derivative Assay, Expressing, Western Blot, Gene Expression, Immunohistochemical staining, Staining, Two Tailed Test

Journal: Redox Biology

Article Title: Targeting HIF-1α promotes ferroptosis and boosts antitumor immunity in MSS colorectal cancer

doi: 10.1016/j.redox.2026.104151

Figure Lengend Snippet: P4HA1 was a major factor regulated by HIF-1α and was enriched in ferroptosis-resistant cells. (A) Venn diagram screening 10 genes commonly induced by hypoxia and the glycolysis pathway in SW480 and WiDr by single-cell sequencing. (B) Gene expression heatmap showed the distribution of genes in different clusters in the presence or absence of RSL3. D: DMSO, R: RSL3. (C) Correlation between ferroptosis suppressor score and P4HA1 in MSS CRC containing 119 patients using Pearson's method. (D) Kaplan-Meier plots of RFS in MSS colon cancer patients according to P4HA1 expression. (E) The correlation between HIF-1α and P4HA1 was evaluated by Spearman's analysis in a colon adenocarcinoma cohort of 457 patients. (F) Relative P4HA1 mRNA expression after HIF-1α knockdown, detected by qPCR. (G) Relative P4HA1 protein expression after HIF-1α knockdown, detected by Western blot. (H) Relative P4HA1 mRNA expression after HIF-1α overexpression, detected by qPCR. (I) Relative P4HA1 protein expression after HIF-1α overexpression, detected by Western blot. (J) Relative P4HA1 expression, detected by qPCR. (K) HIF-1α binding motif predicted from JASPAR. (L) The prospective binding site of HIF-1α on the promoter of P4HA1. (M) ChIP assay of HIF-1α and IgG in parental CT26 cells or Re-CT26 cells, followed by qPCR for the binding sequences.

Article Snippet: The human MSS CRC cell lines SW480, HT-29, and WiDr, human HEK293T, and mouse MSS CRC cell line CT26 were obtained from American Type Culture Collection (ATCC).

Techniques: Single Cell, Sequencing, Gene Expression, Expressing, Knockdown, Western Blot, Over Expression, Binding Assay

Journal: Redox Biology

Article Title: Targeting HIF-1α promotes ferroptosis and boosts antitumor immunity in MSS colorectal cancer

doi: 10.1016/j.redox.2026.104151

Figure Lengend Snippet: HIF-1α inhibition enhanced ferroptosis inducer sensitivity in MSS CRC cells. (A and B) Cell viability of HT-29 or SW480 treated with RSL3, BAY 87-2243 alone or in combination treatment. (C and D) DCFH-DA oxidation in HT-29 or SW480 treated with RSL3, BAY 87-2243 alone or in combination treatment were quantified using flow cytometry with DCFH-DA probe. (E and F) Lipid peroxidation levels of HT-29 or SW480 treated with RSL3, BAY 87-2243 alone or in combination treatment were detected using flow cytometry with C11-BODIPY 581/591 (FITC channel; excitation/emission: 488/510 nm). (G) MDA levels in cells subjected to the indicated treatment. (H) GSH levels in cells subjected to the indicated treatment. Results are shown as means ± SD. ∗ P < 0.05 ; ∗∗ P < 0.01 ; ∗∗∗ P < 0.001 ; ∗∗∗∗ P < 0.0001 . P values were calculated by one-way ANOVA.

Article Snippet: The human MSS CRC cell lines SW480, HT-29, and WiDr, human HEK293T, and mouse MSS CRC cell line CT26 were obtained from American Type Culture Collection (ATCC).

Techniques: Inhibition, Flow Cytometry

Journal: Oncology Letters

Article Title: Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment

doi: 10.3892/ol.2026.15546

Figure Lengend Snippet: Isolation, characterization and cellular internalization of PELNs. (A) Schematic diagram of the preparation process for isolating PELNs from the peel of Punica granatum. (B) Representative transmission electron microscopy image of PELNs. Scale bar, 200 nm (left); 100 nm (right). (C) PELN concentration and size distribution. (D) Zeta potential distribution of PELNs. (E) PKH26-labeled PELNs (red) were received by SW480 cells [nuclei stained by DAPI (blue)]. Scale bar, 25 µm. PELNs, pomegranate peel-derived exosome-like nanoparticles; UC, ultracentrifugation; PBS, phosphate-buffered saline.

Article Snippet: The CRC cell line SW480 utilized in the present study was obtained from Procell Life Science & Technology Co., Ltd. SW480 cells were cultured in Dulbecco's Modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; HyCloneTM; Cytiva) and 1% penicillin/streptomycin (PS) solution in a 37°C cell culture incubator with 5% CO 2 .

Techniques: Isolation, Transmission Assay, Electron Microscopy, Concentration Assay, Zeta Potential Analyzer, Labeling, Staining, Derivative Assay, Saline

Journal: Oncology Letters

Article Title: Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment

doi: 10.3892/ol.2026.15546

Figure Lengend Snippet: Proliferation and apoptosis of SW480 cells after treatment with PELNs. (A and B) Schematic and quantitative diagrams of proliferation of SW480 cells treated with PBS or PELNs. Data are presented as the mean ± SD (n=5). (C and D) Schematic and quantitative diagrams of clone formation of SW480 cells treated with PBS or PELNs. Data are presented as the mean ± SD (n=3). (E and F) Schematic and quantitative diagrams of flow cytometric analysis of SW480 cell apoptosis treated with PBS or PELNs. Data are presented as the mean ± SD (n=3). **P<0.01 and ***P<0.001. PELNs, pomegranate peel-derived exosome-like nanoparticles; PBS, phosphate-buffered saline; ns, not significant.

Article Snippet: The CRC cell line SW480 utilized in the present study was obtained from Procell Life Science & Technology Co., Ltd. SW480 cells were cultured in Dulbecco's Modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; HyCloneTM; Cytiva) and 1% penicillin/streptomycin (PS) solution in a 37°C cell culture incubator with 5% CO 2 .

Techniques: Derivative Assay, Saline

Journal: Oncology Letters

Article Title: Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment

doi: 10.3892/ol.2026.15546

Figure Lengend Snippet: SW480 cell migration after treatment with PELNs. (A and B) Schematic and quantitative diagrams of wound healing of SW480 cells treated with PBS or PELNs. (C and D) Schematic and quantitative diagrams of Transwell migration of SW480 cells treated with PBS or PELNs. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01 and ***P<0.001. PELNs, pomegranate peel-derived exosome-like nanoparticles; PBS, phosphate-buffered saline; ns, not significant.

Article Snippet: The CRC cell line SW480 utilized in the present study was obtained from Procell Life Science & Technology Co., Ltd. SW480 cells were cultured in Dulbecco's Modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; HyCloneTM; Cytiva) and 1% penicillin/streptomycin (PS) solution in a 37°C cell culture incubator with 5% CO 2 .

Techniques: Migration, Derivative Assay, Saline

Journal: Oncology Letters

Article Title: Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment

doi: 10.3892/ol.2026.15546

Figure Lengend Snippet: Anti-colorectal cancer molecular mechanism of PELNs. (A) Sample correlation analysis heat map. (B and C) Volcano plot map and cluster analysis diagram of differentially expressed genes in SW480 cells treated with phosphate-buffered saline or PELNs. (D and E) Balloon plots of KEGG pathway (top 20) and GO term enrichment (top 20) analyses. PELNs, pomegranate peel-derived exosome-like nanoparticles; KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology.

Article Snippet: The CRC cell line SW480 utilized in the present study was obtained from Procell Life Science & Technology Co., Ltd. SW480 cells were cultured in Dulbecco's Modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; HyCloneTM; Cytiva) and 1% penicillin/streptomycin (PS) solution in a 37°C cell culture incubator with 5% CO 2 .

Techniques: Saline, Derivative Assay

Journal: iScience

Article Title: Mechanism-based prediction of drug synergy via network controllability analysis of therapeutic pathways in intractable diseases

doi: 10.1016/j.isci.2026.115339

Figure Lengend Snippet: In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, lucitanib; Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.

Article Snippet: The HT-29 human CRC cell line (HTB-38; ATCC) was obtained from the ATCC (Rockville, MD, USA).

Techniques: In Vitro, Biomarker Discovery, Comparison, Standard Deviation